Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Kamal S. Saini; Carlo Lanza; Marco Romano; Evandro de Azambuja; Javier Cortes; Begoña de las Heras; Javier de Castro; Monika Lamba Saini; Sibylle Loibl; Giuseppe Curigliano; Chris Twelves; Manuela Leone; Mrinal M. Patnaik

doi:10.1038/s41416-020-0948-x

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Kamal S. Saini, Carlo Lanza, Marco Romano, Evandro de Azambuja, Javier Cortes, Begoña de las Heras, Javier de Castro, Monika Lamba Saini, Sibylle Loibl, Giuseppe Curigliano, Chris Twelves, Manuela Leone, Mrinal M. Patnaik

Hematology

Research output: Contribution to journal › Comment/debate › peer-review

10 Scopus citations

Abstract

Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.

Original language	English (US)
Pages (from-to)	694-697
Number of pages	4
Journal	British journal of cancer
Volume	123
Issue number	5
DOIs	https://doi.org/10.1038/s41416-020-0948-x
State	Published - Sep 1 2020

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/s41416-020-0948-x

Cite this

Saini, K. S., Lanza, C., Romano, M., de Azambuja, E., Cortes, J., de las Heras, B., de Castro, J., Lamba Saini, M., Loibl, S., Curigliano, G., Twelves, C., Leone, M., & Patnaik, M. M. (2020). Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. British journal of cancer, 123(5), 694-697. https://doi.org/10.1038/s41416-020-0948-x

Saini, KS, Lanza, C, Romano, M, de Azambuja, E, Cortes, J, de las Heras, B, de Castro, J, Lamba Saini, M, Loibl, S, Curigliano, G, Twelves, C, Leone, M & Patnaik, MM 2020, 'Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy', British journal of cancer, vol. 123, no. 5, pp. 694-697. https://doi.org/10.1038/s41416-020-0948-x

@article{0ee326b06d2441df9f09726182767339,

title = "Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy",

abstract = "Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.",

author = "Saini, {Kamal S.} and Carlo Lanza and Marco Romano and {de Azambuja}, Evandro and Javier Cortes and {de las Heras}, Bego{\~n}a and {de Castro}, Javier and {Lamba Saini}, Monika and Sibylle Loibl and Giuseppe Curigliano and Chris Twelves and Manuela Leone and Patnaik, {Mrinal M.}",

note = "Publisher Copyright: {\textcopyright} 2020, Cancer Research UK.",

year = "2020",

month = sep,

day = "1",

doi = "10.1038/s41416-020-0948-x",

language = "English (US)",

volume = "123",

pages = "694--697",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

AU - Saini, Kamal S.

AU - Lanza, Carlo

AU - Romano, Marco

AU - de Azambuja, Evandro

AU - Cortes, Javier

AU - de las Heras, Begoña

AU - de Castro, Javier

AU - Lamba Saini, Monika

AU - Loibl, Sibylle

AU - Curigliano, Giuseppe

AU - Twelves, Chris

AU - Leone, Manuela

AU - Patnaik, Mrinal M.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.

AB - Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.

UR - http://www.scopus.com/inward/record.url?scp=85086774432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086774432&partnerID=8YFLogxK

U2 - 10.1038/s41416-020-0948-x

DO - 10.1038/s41416-020-0948-x

M3 - Comment/debate

C2 - 32572174

AN - SCOPUS:85086774432

SN - 0007-0920

VL - 123

SP - 694

EP - 697

JO - British journal of cancer

JF - British journal of cancer

IS - 5

ER -

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this